🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Pozzilli
Clinical trial register · Italy

Clinical Trials in Pozzilli, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6830 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:52 UTC
6830
Studies in scope
all four open statuses
4109
Recruiting now
open to new participants
1019
Lead sponsors
across recruiting studies
Top sites
Milan 2849 Bologna 1313 Roma 1277 Naples 984 Rome 980
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Neuromed IRCCS8 Novartis Pharmaceuticals5 Hoffmann-La Roche4 Zenas BioPharma (USA), LLC3 Takeda2
Site location
Milan2849 Bologna1313 Roma1277 Naples984 Rome980
All 483 locations
Target enrolment
to

Trials with a site in Pozzilli

35 of 6830 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Not yet open
Italian Validation of the dNA Scale and Its Correlation With Neurocognitive Variables
NCT07533084Active Aging Individuals Aged 65 and Over, Aging, Mild Cognitive Impairment (MCI), Dementia
Neuromed IRCCS
Observational
265
Brescia, Genova, Pozzilli, Milan, Pavia, Roma, Venezia
2026-09
Recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263Cardiovascular Disease and Lipoprotein(a)
DrugPelacarsen
Novartis Pharmaceuticals
Phase 3
5,700
Ancona, Bergamo, Bologna, Brescia, Cona, Florence, Pozzilli, Milan
2026-05-11
Recruiting
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463Multiple Sclerosis (MS) Primary Progressive
DrugOrelabrutinib
Zenas BioPharma (USA), LLC
Phase 3
705
Pozzilli
2026-03-23
Recruiting
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019Secondary Progressive Multiple Sclerosis
DrugOrelabrutinib
Zenas BioPharma (USA), LLC
Phase 3
990
Pozzilli
2026-03-23
Recruiting
Poland-Italy Aortic Research Bridge Real World Registry
NCT07476196Abdominal Aortic Aneurysm
American Heart of Poland
Observational
200
Castel Volturno, Catania, Pozzilli, Reggio Emilia, San Donato Milanese
2026-03-01
Recruiting
Precision Medicine and Neurodegenerative Diseases: Advanced Systems for the Diagnosis and Treatment of Parkinson's Disease and Alzheimer's Disease.
NCT07467460PARKINSON DISEASE (Disorder), Alzheimer s Disease, Diabete Type 2
Neuromed IRCCS
Observational
500
Pozzilli
2026-02-17
Active, closed
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
NCT07074886Multiple Sclerosis
Hoffmann-La Roche
Phase 2
193
Foggia, Naples, Rome, Milan, Pozzilli
2025-11-13
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
1,275
Ancona, Bergamo, Foggia, Pozzilli, Pavia, Roma, Gallarate, Naples
2025-11-11
By invitation
Clinical Trial of Vormatrigine in Adult Patients With Epilepsy
NCT07287163Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure
Praxis Precision Medicines
Phase 3
700
Pozzilli, Bosisio Parini, Milan, Naples, Pavia, Pisa, Ponderano, Roma
2025-10-27
Recruiting
Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease
NCT06965374Parkinson Disease
AbbVie
Observational
270
Troina, Pozzilli, Milan, Naples, Turin, Rome, Venice, Ancona
2025-06-04
Not yet open
Transcranial Static Field Stimulation (tSMS) and Transcranial Direct Current Stimulation (tDCS) for the Treatment of Neurological Symptoms.
NCT06900959Neurological Diseases or Conditions
Neuromed IRCCS
Not applicable
40
Pozzilli
2025-05-11
Recruiting
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
NCT05066217Lennox Gastaut Syndrome
DrugClemizole HCl
Epygenix
Phase 3
260
Genoa, Pozzilli, Catanzaro, Florence, Milan
2025-04-09
Active, closed
Racial Disparities in Acute Stroke
NCT06955442Ischemic Stroke
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Observational
4,500
Bologna, Crema, Frosinone, Genova, Lecce, Naples, Pavia, Pozzilli
2025-04-03
Recruiting
A Study of TAK-360 in Adults With Idiopathic Hypersomnia
NCT06812078Idiopathic Hypersomnia
DrugTAK-360
Takeda
Phase 2
96
Pozzilli, Rome, Verona, Bologna
2025-02-07
Recruiting
Discovery and Validation of Protein Structural Complexes in Circulating Biofluids As Novel Biomarkers for Early Diagnosis, Prognosis and Therapeutic Management of Patients Affected by Neurodegenerative Disorders
NCT06803784Parkinson Disease, Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Alzheimer's Disease (AD)
Neuromed IRCCS
Observational
110
Pozzilli
2025-02-04
Recruiting
Novel Risk Prediction Approaches for the Primary Prevention of Cardiovascular Diseases in Italy: the CVRISK-IT Trial (CVRISK-IT)
NCT06832644Cardiovascular Risk, Genetic Cardiovascular Risk
IRCCS Policlinico S. Donato
Not applicable
30,000
Milan, Ancona, Genova, Naples, Palermo, Pavia, Pozzilli, Rome
2025-01-22
Recruiting
A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
NCT06752668Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
DrugORX750
Centessa Pharmaceuticals (UK) Limited
Phase 2
248
Bologna, Pozzilli, Verona
2024-12-23
Recruiting
Wide-Antral Pulmonary Vein Isolation in Atrial Fibrillation Ablation with a Single-shot Technique (WIDER-PVI)
NCT06698159Atrial Fibrillation, Atrial Fibrillation (Paroxysmal)
Hospital Universitario 12 de Octubre
Not applicable
440
Pozzilli, Acerra, Brescia, Latina, Maddaloni, Monza, Naples, Padova
2024-11-01
Active, closed
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
NCT06564311Relapsing Multiple Sclerosis
DrugObexelimab
Zenas BioPharma (USA), LLC
Phase 2
93
Cefalù, Florence, Pozzilli, Roma
2024-08-26
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Pozzilli, Milan, Rome, Florence, Bergamo, Cagliari, Catania, Chieti
2024-04-16
Recruiting
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
NCT05646381Aortic Stenosis
DrugPelacarsen
Novartis Pharmaceuticals
Phase 2
502
Ancona, Bergamo, Bologna, Brescia, Caserta, Cona, Pozzilli, Milan
2024-03-07
Active, closed
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
NCT06047444Chronic Migraine
DrugsDysport·Botulinum toxin type A
Ipsen
Phase 3
759
Bologna, Naples, Pavia, Pozzilli, Roma
2023-10-12
Active, closed
Integrated Management of Atypical Parkinsonism: A Home-based Patient-Centered Healthcare Delivery Based on Telenursing (IMPACT Study)
NCT05792332Atypical Parkinsonism, MSA - Multiple System Atrophy, PSP, Nurse-Patient Relations
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Not applicable
164
Messina, Milan, Pavia, Pozzilli
2023-08-17
Recruiting
Effects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple Sclerosis
NCT05811013Progressive Multiple Sclerosis
Neuromed IRCCS
Not applicable
40
Pozzilli
2023-05-27
Recruiting
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
NCT05816382Narcolepsy Type 1
DrugTAK-861
Takeda
Phase 2/3
500
Rome, Pozzilli, Bellaria
2023-04-05
Active, closed
Cenobamate in Adults With Focal-Onset Seizures
NCT05859854Epilepsy, Focal-Onset Seizure, Neurological Disorder
Aziende Chimiche Riunite Angelini Francesco S.p.A
Observational
936
Bari, Catanzaro, Pozzilli, Pavia, Roma, Torino, Conegliano, Udine
2023-01-24
Recruiting
Functional Study of Inhibitory Neurotransmission in the Human Epileptic Brain.
NCT05459090Drug Resistant Epilepsy
Neuromed IRCCS
Observational
60
Pozzilli
2022-07-29
By invitation
Psychometric Evaluation in Patients With Brain Damage During Neuroinflammation
NCT05450237Multiple Sclerosis, Epilepsy, Parkinson Disease, Dementia
Neuromed IRCCS
Observational
500
Pozzilli
2022-07-01
Active, closed
Italian Digital Primary Cardiovascular Prevention Study
NCT05339841Healthy Population
Centro Cardiologico Monzino
Not applicable
27,520
Scafa, Martano, Reggio Calabria, Benevento, Salerno, Carpi, Pradamano, Pozzilli
2022-06-10
Active, closed
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
NCT05156281Relapsing Multiple Sclerosis
DrugsTeriflunomide·Remibrutinib
Novartis Pharmaceuticals
Phase 3
1,007
Brindisi, Foggia, Pozzilli, Messina, Modena, Pavia, Orbassano, Naples
2021-12-13
Active, closed
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428Atherosclerotic Cardiovascular Disease
DrugInclisiran sodium
Novartis Pharmaceuticals
Phase 3
17,004
Bologna, Brescia, Cona, Florence, Grosseto, Pozzilli, Milan, Rozzano
2021-11-23
Active, closed
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
NCT04544436Multiple Sclerosis
DrugsOcrelizumab·Methylprednisolone
Hoffmann-La Roche
Phase 3
864
Chieti, Naples, Rome, Milan, Pozzilli
2020-11-26
Active, closed
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
NCT04544449Multiple Sclerosis, Primary Progressive
DrugsFenebrutinib·Ocrelizumab
Hoffmann-La Roche
Phase 3
985
Naples, Parma, Rome, Genoa, Milan, Montichiari, Pozzilli, Palermo
2020-10-26
Active, closed
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
NCT03523858Progressive Multiple Sclerosis (PMS)
DrugOcrelizumab
Hoffmann-La Roche
Phase 3
927
Bari, Naples, Trieste, Rome, Genoa, Milan, Pavia, Pozzilli
2018-05-28
Recruiting
Biomarkers of Synaptic Damage in Multiple Sclerosis
NCT03217396Multiple Sclerosis, Parkinson Disease, Amyotrophic Lateral Sclerosis, Alzheimer Disease
Neuromed IRCCS
Observational
300
Pozzilli
2017-11-22
Rows per page Showing 1–35 of 35
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-italy/city/pozzilli

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,830 studies in total at the last sync on 26 Sep 2026, 19:52 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 35 of those studies with a site in Pozzilli.

How many clinical trials are recruiting in Pozzilli?

18 of the 35 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:52 UTC sync. A further 2 have not yet opened recruitment, 13 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Pozzilli), 35 studies
PhaseStudiesRecruitingShare
Phase 313537.1%
Observational10628.6%
Not applicable6317.1%
Phase 25314.3%
Phase 2/3112.9%

Most active sponsors

Lead sponsors with the most studies (Pozzilli)
Lead sponsorStudiesRecruiting
Neuromed IRCCS85
Novartis Pharmaceuticals53
Hoffmann-La Roche40
Zenas BioPharma (USA), LLC32
Takeda22
AbbVie11
American Heart of Poland11
Aziende Chimiche Riunite Angelini Francesco S.p.A10
Centessa Pharmaceuticals (UK) Limited11
Centro Cardiologico Monzino10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.